UltraGreen.ai (SGX:ULG
) announced that it secured regulatory approval for Verdye (indocyanine green for injection) in Singapore.
The company believes this approval is a strategic step in its Southeast Asia growth strategy, which will help in expanding its addressable market and strengthening its presence in a key regional healthcare hub.
“Singapore plays a critical role as a centre for clinical excellence and regional influence, supporting broader adoption of advanced surgical technologies across Southeast Asia,” the company adds.
Through the approval, it will enable Utragreen.ai to advance commercialisation efforts, deepen partnerships with leading healthcare institutions, and support clinical adoption of fluorescence-guided surgery.
“This approval reinforces our strong regulatory execution and clear momentum in our regional strategy. We are well positioned to support surgeons with proven fluorescence-guided solutions while laying the groundwork for continued growth and innovation across Southeast Asia,” says Ravi Sajwan, CEO of Ultragreen.ai.
As at 10.23am, shares in UltraGreen.ai are trading 7 US cents lower, or 4.69% down at US$1.42.
